Neoantigen Peptide Manufacturing
Prompt delivery of custom Neoantigen peptides characterized as critical raw materials in Emergency IND (EIND) use. They are suitable for such applications as ex-vivo T-cell therapy, vaccine development, or other personalized cancer immunotherapies*.
*Not for individual use; available to approved organizations only.
Privileged Partner for project-based management
We can execute individual peptide manufacturing batches for multiple projects concurrently. Production slot reservations can be organized to optimize delivery schedules.
Key advantages of the service
We are your CMO for custom Neoantigen manufacturing and consistently strive to exceed expectations in quality and service. For nearly 30 years, our customers have leveraged our vast expertise in peptide synthesis and combinatorial chemistry to help achieve their goals.
We have the expertise and the technical know-how to manufacture the highest quality of Neoantigen peptides promply.
We are pioneers in peptide technology & combinatorial chemistry innovations.
Dedicated Project Manager
We guarantee that you will be kept updated throughout the entire production process.
All materials and processes are traceable using batch production records and robust standard operating procedures.
IND filling support with complete Chemistry, Manufacturing and Control (CMC) package.
All Neoantigen peptides are manufactured in our certified ISO 7 classified cleanrooms (10,000) using our stringent QMS.
Your project from start to finish
Your dedicated project manager will be your liaison to guide you from the
initial discussions on CDA and MSA agreements, to manufacturing,
testing and product release.
CDA & supplier contracts, product specifications, customer audits.
Small scale production using released raw materials for feasibility.
Identification & setting of critical manufacturing parameters.
Cleanroom manufacturing of the peptides under our QMS using Batch Production Records & SOP’s.
QC release of the product followed by QA review of the manufacturing/testing records, shipping.
Neoantigen vaccines for immunotherapy
Cancer sporadically originates from normal tissues through the accumulation of genetic and epigenetic aberrations.
This genetic instability of cancer cells often leads to the production of abnormal tumor proteins not found in normal cells, called Tumor-Specific Neoantigens (TSNAs), which pose promising opportunities for the development of new vaccines.
Therapeutic cancer vaccines act by inducing tumor degradation, eliminating minimal residual disease, and creating continuous anticancer memory.